Vaccitech Announces Pricing of Initial Public Offering

29 April 2021

Oxford, UK – Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of $110.5 million. All ADSs sold in the offering are being offered by Vaccitech. The ADSs are expected to begin trading on The Nasdaq Global Market on April 30, 2021 under the ticker symbol “VACC.” In addition, Vaccitech has granted the underwriters a 30-day option to purchase up to an additional 975,000 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2021, subject to satisfaction of customary closing conditions.

Morgan Stanley, Jefferies, Barclays and William Blair are acting as book-runners for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

A registration statement on Form S-1 relating to these securities was declared effective on April 29, 2021. The securities referred to in this announcement are being offered only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@jefferies.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at barclaysprospectus@broadridge.com or telephone at 1-888-603-5847; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media contacts:

Katja Stout, Scius Communications (EU)

Direct: +44 (0) 7789435990

Email: katja@sciuscommunications.com

Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

212-213-0006 ext. 315 / 364

Email: rimai@burnsmc.com / rflamm@burnsmc.com

Henry Hodge, Vaccitech

Direct: +44 (0) 7533 421 442

Email: henry.hodge@vaccitech.co.uk

Read other news articles